ACADIA Pharmaceuticals 2019 Annual Report

Biotech company focused on developing innovative medicines for CNS disorders, with strong commercial growth of NUPLAZID for Parkinson's disease psychosis and advancing late-stage clinical programs in dementia-related psychosis, major depressive disorder, schizophrenia, and Rett syndrome.